39 The study of these clinical properties in small molecule GLP-1RAs is an undergoing area of study
The FDAs 2023 placement of BPC-157 (and related research peptides) in the interim category of bulk substances that may present significant safety risks was based on gaps in physicochemical characterization, immunogenicity concerns, impurity risks, and a lack of human safety data
Compounders offering such blended products tend to claim that these extra ingredients, which are commonly used as nutritional supplements, can prevent muscle loss, improve sleep quality, or even improve weight loss results
An important consideration is that most published research uses injectable EpitalON, while YourProtocol offers an oral formulation
However, it is still used daily but offers more flexibility in timing